ArticleBMC gastroenterology2025
Role of procalcitonin in identifying systemic inflammatory response syndrome and sepsis in acute-on-chronic liver failure and its impact on survival.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Changes in C-reactive Protein and Procalcitonin as Predictors of 28-day Mortality in Acute-on-chronic Liver Failure: A Prospective Observational Study from Northeast India.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammatory response syndrome (SIRS) and sepsis are commonly observed in patients with acute-on-chronic liver failure (ACLF). This study aimed to identify the presence of SIRS and sepsis in ACLF patients to assess their impact on patient survival and the role of procalcitonin (PCT) in identifying SIRS and sepsis. METHODOLOGY: This prospective study was performed at a tertiary hospital in India from August 2023 to August 2024. Patients with ACLF according to the APASL classification were included in the study. These patients were assessed for the presence or absence of SIRS or sepsis at baseline and monitored until day 7, and clinical outcome was evaluated on day 28.
resultsA total of 135 patients with a median age of 44 years (IQR: 38–51) and a male predominance (98.5%, 133/135) were included in the study. Alcohol was the primary cause of ACLF in 88.1% of patients. Among these patients, SIRS was present in 59.2% of patients, while sepsis was present in 42.2%. Patients with SIRS and sepsis had significantly higher median MELD-Na, AARC, and CLIF-SOFA scores than those without SIRS and sepsis (p < 0.001). The 28-day mortality rate was greater in the SIRS group (60%) and sepsis group (59.64%) than in the non-SIRS group (p < 0.001). Furthermore, PCT was demonstrated as a significant independent predictor of mortality (OR 1.45, 95% CI: 1.12–1.89, p = 0.004).
conclusionSepsis and SIRS are common in ACLF patients and carry a high mortality risk. PCT measurement may be used to detect SIRS and sepsis in these patients early and can be used to guide prompt intervention to improve the outcome of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.